Project Grant R01CA315957
Award Date 8/11/26
Completion Date 7/31/31
Dollars Obligated $522K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
South Miami, FL 33146, USA
Similar Awards
- The National Cancer Institute awarded University of Miami $322,563 on September 23, 2025, under the Cancer Cause and Prevention Research program (CFDA 93.393) to investigate racial disparities in breast cancer risk and gene expression by examining the roles of genetic and lifestyle factors. The recipient will recruit 250 African Zambian women with pathologically confirmed breast cancer at the Cancer Disease Hospital in Lusaka, Zambia, collect clinical and lifestyle data, obtain tumor tissue...
- The National Cancer Institute awarded the University of Pittsburgh $673,522 on July 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to support comprehensive biochemical and structural analysis of nucleotide excision repair (NER), the primary human pathway for removing DNA lesions caused by solar UV irradiation and environmental toxins. The recipient will characterize the dynamic progression of NER from damage recognition and verification through dual incision, using...
- The National Cancer Institute awarded the University of Miami $164,190 under the Cancer Research Manpower program (CFDA 93.398) on December 17, 2025, to support biomedical training in basic, clinical, and prevention research relevant to the National Cancer Program. The project, titled "Immuno-Modulating Diffuse Midline Glioma by Epi-Transcriptomic Reprogramming," runs through September 1, 2029, with performance at the University of Miami's Office of Research Administration—School of...
- The National Cancer Institute awarded the University of Miami $529,260 on June 22, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate lactic acid sensing as a therapeutic vulnerability in clear cell renal cell carcinoma. The research examines the role of extracellular lactate in the tumor microenvironment as a self-signal driving tumor aggressiveness. The recipient has identified the G-protein coupled receptor GPR132 as a tumor dependency mechanism and proposes it...
- The National Cancer Institute, part of the Department of Health and Human Services National Institutes of Health, awarded New York University $701,574 on August 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to investigate APOBEC3-induced mutagenesis in cancer development and therapy resistance. The funded research develops experimental and bioinformatics methods to track de novo generation of specific mutational signatures (SBS2 and SBS13) induced by individual...
- The National Cancer Institute awarded the University of Miami $547,621 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate (R)-ND336, a selective MMP14 inhibitor, as a means to overcome therapeutic resistance in glioblastoma and enhance response to chemoradiation and immunotherapy. The research addresses glioblastoma's "cold" tumor microenvironment and poor immunotherapy response by targeting MMP14, which stabilizes replication forks and...
- The National Cancer Institute awarded the University of Miami $606,219 on July 2, 2026, under the Cancer Biology Research program (CFDA 93.396) to support signal transduction, cell biology, and molecular pharmacology research on the olfactory G protein-coupled receptor OR51E1. The recipient is developing high-throughput screening and computational platforms to identify novel small-molecule agonists and antagonists for OR51E1, an olfactory receptor expressed ectopically in prostate cancer and...
- The National Cancer Institute, part of the Department of Health and Human Services, awarded the University of Texas at Austin $396,377 on May 7, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to characterize mutational signatures at hotspots of genetic instability in human cancer genomes. The project integrates large-scale cancer genome analyses, gene perturbation experiments, and environmental mutagen exposure data to uncover the mutational processes driving...
- The National Cancer Institute awarded the University of Maryland, College Park $369,075 on June 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop computational methods for reconstructing transposable element activity in cancer genomes using long-read sequencing and local assembly approaches. The project addresses a fundamental gap in cancer genomics: somatic transposition events—insertions where DNA sequences jump or copy themselves to new genomic locations—occur in...
- The National Cancer Institute awarded the University of Chicago $547,740 on July 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to define the molecular mechanisms by which the MLL1 histone modification complex and the long noncoding RNA HOTTIP interact in acute myeloid leukemia pathogenesis. The research examines whether non-specific RNA binding to the WDR5 subunit of the MLL1 complex inhibits the complex's histone methyltransferase activity and whether the RBBP5...